GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy
The FDA has granted accelerated approval to GSK’s tyrosine kinase inhibitor neladalkib for ALK-positive non-small cell lung cancer, marking the…
The FDA has granted accelerated approval to GSK’s tyrosine kinase inhibitor neladalkib for ALK-positive non-small cell lung cancer, marking the…